Myeloid/natural killer (NK) cell precursor acute leukemia as a distinct leukemia type.
Nishimura A, Yokoyama K, Naruto T, Yamagishi C, Imamura T, Nakazono H, Kimura S, Ito M, Sagisaka M, Tanaka Y, Piao J, Namikawa Y, Yanagimachi M, Isoda T, Kanai A, Matsui H, Isobe T, Sato-Otsubo A, Higuchi N, Takada A, Okuno H, Saito S, Karakawa S, Kobayashi S, Hasegawa D, Fujisaki H, Hasegawa D, Koike K, Koike T, Rai S, Umeda K, Sano H, Sekinaka Y, Ogawa A, Kinoshita A, Shiba N, Miki M, Kimura F, Nakayama H, Nakazawa Y, Taga T, Taki T, Adachi S, Manabe A, Koh K, Ishida Y, Takita J, Ishikawa F, Goto H, Morio T, Mizutani S, Tojo A, Takagi M.
Sci Adv. 2023 Dec 15;9(50):eadj4407. doi: 10.1126/sciadv.adj4407. Epub 2023 Dec 13.
PMID:38091391
Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?
Sanchez-Correa B, Campos C, Pera A, Bergua JM, Arcos MJ, Bañas H, Casado JG, Morgado S, Duran E, Solana R, Tarazona R.
Cancer Immunol Immunother. 2016 Apr;65(4):453-63. doi: 10.1007/s00262-015-1720-6. Epub 2015 Jun 10.
PMID:26059279
Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia.
Wang Y, Huang B, Liang T, Jiang L, Wu M, Liu X, Zhu M, Song X, Zhao N, Wei H, Zheng C, Ni F.
Cell Rep Med. 2024 Jun 18;5(6):101580. doi: 10.1016/j.xcrm.2024.101580. Epub 2024 May 21.
PMID:38776913
Natural killer cell-triggering receptors in patients with acute leukaemia.
Fauriat C, Marcenaro E, Sivori S, Rey J, Gastaut JA, Moretta A, Olive D, Costello RT.